JP2012515754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515754A5 JP2012515754A5 JP2011546964A JP2011546964A JP2012515754A5 JP 2012515754 A5 JP2012515754 A5 JP 2012515754A5 JP 2011546964 A JP2011546964 A JP 2011546964A JP 2011546964 A JP2011546964 A JP 2011546964A JP 2012515754 A5 JP2012515754 A5 JP 2012515754A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- medicament
- compounds
- composition
- glycosylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 22
- 229940079593 drug Drugs 0.000 claims 14
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 claims 6
- GMBQZIIUCVWOCD-UQHLGXRBSA-N (25R)-5beta-spirostan-3beta-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000002576 ketones Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 3
- LLBKWFWTEWVDKM-UHFFFAOYSA-N 5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-15,16,17-triol Chemical compound CC1C(C2(CCC3C4(C)CC(O)C(O)C(O)C4CCC3C2C2)C)C2OC11CCC(C)CO1 LLBKWFWTEWVDKM-UHFFFAOYSA-N 0.000 claims 2
- 235000013361 beverage Nutrition 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- -1 frosten Chemical compound 0.000 claims 2
- 239000000543 intermediate Substances 0.000 claims 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical class 0.000 claims 2
- 229950002323 smilagenin Drugs 0.000 claims 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 claims 1
- GMBQZIIUCVWOCD-RHHRBMONSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16R,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-RHHRBMONSA-N 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- FWCXELAAYFYCSR-UHFFFAOYSA-N Episamogenin Natural products CC1C(C2(CCC3C4(C)CC(O)C(O)CC4CCC3C2C2)C)C2OC11CCC(C)CO1 FWCXELAAYFYCSR-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 1
- 229930194542 Keto Natural products 0.000 claims 1
- RYCUBFVMMAWZKH-UHFFFAOYSA-N Metagenin Natural products CC1C(C2(CC(O)C3C4(C)CC(O)C(O)CC4CCC3C2C2)C)C2OC11CCC(C)CO1 RYCUBFVMMAWZKH-UHFFFAOYSA-N 0.000 claims 1
- PBLXVDNSLUFVHF-UHFFFAOYSA-N Neomanogenin Natural products CC1C(C2(C(=O)CC3C4(C)CC(O)C(O)CC4CCC3C2C2)C)C2OC11CCC(C)CO1 PBLXVDNSLUFVHF-UHFFFAOYSA-N 0.000 claims 1
- 206010056677 Nerve degeneration Diseases 0.000 claims 1
- HMMCOAQTWLRBMU-WANIKOBHSA-N O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 Chemical compound O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 HMMCOAQTWLRBMU-WANIKOBHSA-N 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- GMBQZIIUCVWOCD-SGKIHABASA-N epismilagenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-SGKIHABASA-N 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- CTYOUOHIEXEYAW-MEVSNGMESA-N furostane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H]3O[C@H](CCC(C)C)[C@@H](C)[C@@H]3[C@@]1(C)CC2 CTYOUOHIEXEYAW-MEVSNGMESA-N 0.000 claims 1
- FRPYMMBAAIXFOI-UHFFFAOYSA-N furostane Natural products CC(CCC1(O)OC2CC3C4CCC5CC(OC6OC(C)C(O)C(O)C6OC7OC(C)C(O)C(O)C7O)C(O)CC5(C)C4CCC3(C)C2C1C)COC8OC(CO)C(O)C(O)C8O FRPYMMBAAIXFOI-UHFFFAOYSA-N 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- RYCUBFVMMAWZKH-OGQYGRRHSA-N metagenin Chemical compound O([C@@H]1[C@@H]([C@]2(C[C@@H](O)[C@@H]3[C@@]4(C)C[C@H](O)[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 RYCUBFVMMAWZKH-OGQYGRRHSA-N 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- INLFWQCRAJUDCR-LYLBMTSKSA-N spirostane Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 INLFWQCRAJUDCR-LYLBMTSKSA-N 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- SORUXVRKWOHYEO-UHFFFAOYSA-N timosaponin B-II Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O SORUXVRKWOHYEO-UHFFFAOYSA-N 0.000 claims 1
- UDUSTUNNFSNCPR-QFNYSWOCSA-N timosaponin BII Natural products C[C@H](CC[C@@]1(O)O[C@H]2C[C@H]3[C@@H]4CC[C@@H]5C[C@H](CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2[C@@H]1C)O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O UDUSTUNNFSNCPR-QFNYSWOCSA-N 0.000 claims 1
- SORUXVRKWOHYEO-UJDJZYEZSA-N timosaponin bii Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SORUXVRKWOHYEO-UJDJZYEZSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims 1
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14708409P | 2009-01-24 | 2009-01-24 | |
| CNPCT/CN2009/070319 | 2009-01-24 | ||
| CN2009070319 | 2009-01-24 | ||
| US61/147,084 | 2009-01-24 | ||
| PCT/GB2010/050098 WO2010084356A1 (en) | 2009-01-24 | 2010-01-22 | Treatment of neurotrophic factor mediated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515754A JP2012515754A (ja) | 2012-07-12 |
| JP2012515754A5 true JP2012515754A5 (cg-RX-API-DMAC7.html) | 2013-03-07 |
Family
ID=41800830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546964A Pending JP2012515754A (ja) | 2009-01-24 | 2010-01-22 | 神経栄養因子介在疾患の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120034193A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2389182A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012515754A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110115589A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010207597A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1005372A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2750510A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201190115A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL214242A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011007842A (cg-RX-API-DMAC7.html) |
| SG (1) | SG173094A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010084356A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130210786A1 (en) * | 2010-07-20 | 2013-08-15 | Patrick Alexander Howson | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
| US8708906B1 (en) * | 2011-09-07 | 2014-04-29 | Allen J. Orehek | Method for the prevention of dementia and Alzheimer's disease |
| RU2501562C1 (ru) * | 2012-11-01 | 2013-12-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук ФГБУ "НИИ фармакологии" СО РАМН | Средство, обладающее церебропротекторной активностью |
| US20160193296A1 (en) * | 2012-12-19 | 2016-07-07 | Brown University | Methods for treatment of microcephaly associated autism disorders |
| WO2017218697A1 (en) * | 2016-06-17 | 2017-12-21 | The Trustees Columbia University In The City Of New York | Identification of compounds that target the rna-binding protein tia-1 an important regulator of stress vulnerability in both mice and humans |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| CN109890381A (zh) * | 2016-09-12 | 2019-06-14 | 南佛罗里达大学 | 酮改善神经再生 |
| FI3558280T3 (fi) | 2016-12-21 | 2023-07-13 | Univ Kinderspital Beider Basel | Migreenin ennaltaehkäisy ja hoito |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US9925164B1 (en) | 2017-01-12 | 2018-03-27 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
| BR102017016550A2 (pt) | 2017-08-01 | 2019-03-19 | Lisis Rojo Gomes | Uso de glicosídeos esteroidais, formulações farmacêuticas, uso de extratos da planta furcraea foetida, processo de obtenção de extratos da planta furcraea foetida e método de tratamento de distúrbios da pele |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| US11617772B2 (en) | 2018-09-11 | 2023-04-04 | Direct Digital Llc | Nutritional supplements and therapeutic compositions comprising probiotics |
| US12396974B2 (en) | 2020-03-27 | 2025-08-26 | KetoneAid | Ketone ester as a therapeutic treatment of Covid-19 and related viral infections |
| KR102779301B1 (ko) | 2021-12-13 | 2025-03-13 | 한국한의약진흥원 | 근위축 개선, 예방 또는 치료용 조성물 |
| CN115282156A (zh) * | 2022-09-05 | 2022-11-04 | 广东海洋大学 | 知母皂苷元在制备防治帕金森病的药物中的应用 |
| KR102553713B1 (ko) * | 2022-11-18 | 2023-07-10 | 고덕상 | 미네랄 촉매제를 이용한 양식어류사료 제조방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0102416A1 (en) | 1982-08-23 | 1984-03-14 | Nutrisearch Company | Blends of egg albumen and whey protein of improved gel strength |
| DK1017379T3 (en) | 1997-03-17 | 2015-02-16 | Btg Int Ltd | Therapeutic compositions comprising ketone compounds and precursors thereof |
| CN1131237C (zh) | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
| DE69943415D1 (de) | 1998-03-26 | 2011-06-16 | Phytopharm Plc Godmanchester | Sarsasapogenin und Smilagenin zur Behandlung kognitiver Störungen |
| GB9923076D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| JP2002524506A (ja) | 1998-09-15 | 2002-08-06 | ビーティージー・インターナショナル・リミテッド | 治療用組成物（ｉｉ） |
| GB9923078D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923077D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US7795218B2 (en) * | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
| DE10162058A1 (de) * | 2001-12-17 | 2003-07-24 | Cospharcon Gmbh | Gefäßaktive, juckreiz- und entzündungslindernde Zubereitung zur Minimierung der unangenehmen Begleiterscheinungen hämorrhoidaler Affekte und Ekzeme im Analbereich sowie als unterstützende Maßnahme zur Intertrigo- und Dekubitus-Prophylaxe bei entsprechend disponierten Personen. |
| IL164161A0 (en) | 2002-03-27 | 2005-12-18 | Phytopharm Plc | Therapeutic methods and uses of sapogenins and their derivatives |
| MXPA04009321A (es) * | 2002-03-27 | 2005-01-25 | Phytopharm Plc | Metodos y usos terapeuticos de sapogeninas y sus derivados. |
| US7354956B2 (en) * | 2002-04-12 | 2008-04-08 | L'oreal | Composition containing a sapogenin and use thereof |
| US20050100531A1 (en) * | 2002-06-13 | 2005-05-12 | John Bienenstock | Probiotic therapies |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| PT1706121E (pt) * | 2004-01-12 | 2008-12-04 | Solvay Pharm Bv | Inibidores de endopeptidase neutra (nep) e endopeptidase humana solúvel (hsep) para profilaxia e tratamento de distúrbios neurodegenerativos |
| KR100880371B1 (ko) * | 2004-02-09 | 2009-01-30 | 레게니온 게엠베하 | Ｃｎｓ 장애의 치료를 위한 ｔｇｆ－ｒ 시그널화 억제제 |
| GB0409567D0 (en) | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
| CN1692914B (zh) | 2004-04-29 | 2010-05-26 | 中国人民解放军军事医学科学院放射医学研究所 | 知母皂苷bⅱ在制备用于防治脑卒中药物或产品中的用途 |
| GB0424528D0 (en) | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
-
2010
- 2010-01-22 MX MX2011007842A patent/MX2011007842A/es not_active Application Discontinuation
- 2010-01-22 AU AU2010207597A patent/AU2010207597A1/en not_active Abandoned
- 2010-01-22 BR BRPI1005372A patent/BRPI1005372A2/pt not_active IP Right Cessation
- 2010-01-22 EP EP10702341A patent/EP2389182A1/en not_active Withdrawn
- 2010-01-22 CA CA2750510A patent/CA2750510A1/en not_active Abandoned
- 2010-01-22 JP JP2011546964A patent/JP2012515754A/ja active Pending
- 2010-01-22 US US13/138,251 patent/US20120034193A1/en not_active Abandoned
- 2010-01-22 KR KR1020117019497A patent/KR20110115589A/ko not_active Ceased
- 2010-01-22 SG SG2011052867A patent/SG173094A1/en unknown
- 2010-01-22 EA EA201190115A patent/EA201190115A1/ru unknown
- 2010-01-22 WO PCT/GB2010/050098 patent/WO2010084356A1/en not_active Ceased
-
2011
- 2011-07-21 IL IL214242A patent/IL214242A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515754A5 (cg-RX-API-DMAC7.html) | ||
| Liao et al. | Enhancement of anti-inflammatory properties of nobiletin in macrophages by a nano-emulsion preparation | |
| Hussain et al. | Ursolic acid derivatives for pharmaceutical use: a patent review (2012-2016) | |
| Lu et al. | Development of organogel-derived capsaicin nanoemulsion with improved bioaccessibility and reduced gastric mucosa irritation | |
| ES2809177T3 (es) | Inhalación de levofloxacino para reducir la inflamación pulmonar | |
| CN102802636B (zh) | 藏花素水解产物 | |
| CN102843922A (zh) | 硝基脂肪酸–认知减退的神经保护和/或抑制 | |
| Mukker et al. | Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids | |
| CN115605092A (zh) | 制剂及其用途 | |
| WO2011026401A1 (zh) | 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途 | |
| Yu et al. | Gypenoside protects cardiomyocytes against ischemia-reperfusion injury via the inhibition of mitogen-activated protein kinase mediated nuclear factor kappa B pathway in vitro and in vivo | |
| Cerasoli Jr | Developing the ideal inhaled corticosteroid | |
| JP2011513437A5 (cg-RX-API-DMAC7.html) | ||
| Bin Jardan et al. | Effects of garden cress, fenugreek and black seed on the pharmacodynamics of metoprolol: An herb-drug interaction study in rats with hypertension | |
| CN105407885B (zh) | 包含ω-3脂肪酸和番茄的番茄红素的组合 | |
| Shi et al. | Preparation of a micro/nanotechnology based multi-unit drug delivery system for a Chinese medicine Niuhuang Xingxiao Wan and assessment of its antitumor efficacy | |
| Jacob et al. | Vesicular carriers for phytochemical delivery: A comprehensive review of techniques and applications | |
| Reolon et al. | Herbal drugs-loaded soft nanoparticles for treating skin disorders: Where do we stand? | |
| JP6820323B2 (ja) | 組成物及びその使用 | |
| CN120676935A (zh) | 运动障碍的治疗组合 | |
| JP2013184949A (ja) | アレルギー性鼻炎用塗付剤 | |
| Ahmadiafshar et al. | Efficacy and safety of inhaled and intranasal corticosteroids | |
| MX2012013056A (es) | Nuevas formas de dosis para cineol. | |
| CA3118877A1 (en) | Composition comprising nigella sativa oil and surface-active agents | |
| Brimson et al. | Rhinacanthus nasutus Extract as a Neuroprotectant |